UTHR
United Therapeutics Corporation
NASDAQ · Healthcare · Biotechnology · US
$487.61
−0.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.2B | 3.2B | 2.9B | 2.3B | 1.9B |
| Cost of Revenue | 437.2M | 384.4M | 309.7M | 257.5M | 146.7M |
| Gross Profit | 2.7B | 2.8B | 2.6B | 2.1B | 1.8B |
| Operating Expenses | |||||
| R&D Expense | 551.5M | 550.0M | 481.0M | 408.0M | 322.9M |
| SG&A Expense | 730.9M | 731.1M | 638.6M | 477.1M | 487.0M |
| General & Admin Expense | 603.9M | 612.5M | 542.3M | 395.3M | 416.2M |
| Selling & Marketing Expense | 127.0M | 118.6M | 96.3M | 81.8M | 70.8M |
| Other Expenses | 31.5M | — | 71.1M | — | — |
| Total Operating Expenses | 1.3B | 1.3B | 1.2B | 885.1M | 809.9M |
| Cost and Expenses | 1.8B | 1.7B | 1.5B | 1.1B | 956.6M |
| Operating Income (EBIT) | 1.4B | 1.5B | 1.4B | 1.2B | 979.7M |
| Non-Operating | |||||
| Interest Income | 162.9M | 192.0M | 199.1M | 162.7M | 45.2M |
| Interest Expense | 12.0M | 19.5M | 42.9M | 59.3M | 32.4M |
| Net Interest Income | 150.9M | 172.5M | 156.2M | 103.4M | 12.8M |
| Other Non-Op Income/Expense | 169.6M | 196.7M | 162.0M | 89.4M | (29.1M) |
| Non-Operating Income (excl Interest) | (181.6M) | (216.2M) | (204.9M) | (148.7M) | (9.3M) |
| EBT (Pre-Tax Income) | 1.6B | 1.7B | 1.5B | 1.3B | 950.6M |
| Income Tax Expense | 262.1M | 379.2M | 343.9M | 289.5M | 223.3M |
| Bottom Line | |||||
| Net Income | 1.3B | 1.3B | 1.2B | 984.8M | 727.3M |
| Earnings from Cont. Ops | 1.3B | 1.3B | 1.2B | 984.8M | 727.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.3B | 1.3B | 1.2B | 984.8M | 727.3M |
| Per Share | |||||
| Basic EPS | $30.23 | $30.13 | $26.44 | $21.04 | $15.98 |
| Diluted EPS | $27.91 | $27.86 | $24.64 | $19.81 | $15.00 |
| Revenue Per Share | $74.05 | $71.84 | $63.66 | $49.73 | $42.56 |
| Shares | |||||
| Basic Shares Outstanding | 42.6M | 44.3M | 45.2M | 46.8M | 45.5M |
| Diluted Shares Outstanding | 45.8M | 47.9M | 48.5M | 49.7M | 48.5M |
| Profitability Metrics | |||||
| EBITDA | 1.7B | 1.8B | 1.7B | 1.4B | 1.0B |
| D&A | 67.3M | 85.6M | 72.5M | 53.2M | 51.3M |
| EBIT | 1.6B | 1.7B | 1.6B | 1.3B | 989.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026